Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

TCT 2021 | Future of myeloma treatment

Ankit Kansagra • 8 Feb 2021
TCT 2021
Multiple Myeloma Antibodies CAR-T

Ankit Kansagra, MD, UT Southwestern Medical Center, Dallas, TX, discusses future directions in the treatment and management of multiple myeloma including novel immunotherapies such as CAR-T and bispecific antibody products in this field, as well as where these therapies fit in the treatment landscape of multiple myeloma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Ankit Kansagra

An analysis on patients with high-risk multiple myeloma 4:06
An analysis on patients with high-risk multiple myeloma
Ankit Kansagra • 16 Dec 2021
Autologous stem cell transplant for POEMS Syndrome 2:56
Autologous stem cell transplant for POEMS Syndrome
Ankit Kansagra • 16 Dec 2021
Real-world treatment patterns & outcomes of functional high-risk myeloma 4:36
Real-world treatment patterns & outcomes of functional high-risk myeloma
Ankit Kansagra • 8 Feb 2021
KarMMa: characterizing incidence of CRS in R/R myeloma 3:53
KarMMa: characterizing incidence of CRS in R/R myeloma
Ankit Kansagra • 8 Feb 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals